You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國抗體-B(03681.HK):SM03報告摘要獲接納在APLAR虛擬大會上作現場口頭陳述
格隆匯 09-28 16:35

格隆匯9月28日丨中國抗體-B(03681.HK)發佈公告,有關公司的旗艦產品SM03獲得亞太風濕病學會聯盟(“APLAR”)的認可的最新進展。 APLAR是一個代表亞太地區不同國家多個風濕病學會成員的聯盟,致力在亞太地區傳揚及促進風濕病學的發展。

2020年8月27日,公司獲APLAR知會,公司早前遞交的報告摘要已獲接納於第22屆APLAR虛擬大會上作現場口頭陳述,該大會現時計劃於2020年10月24日至10月29日舉行。公司遞交的報告摘要題為“抗人CD22單克隆抗體SM03治療中國類風濕關節炎患者的抗藥抗體反應”。此陳述為SM03研究及開發的一部分,將主要介紹SM03治療類風濕關節炎的臨牀研究。繼2020年6月5日在2020年歐洲風濕病學大會上作出口頭陳述後,陳述為有關治療類風濕關節炎SM03臨牀研究報告摘要的第二次國際口頭陳述。

公司的旗艦產品SM03為全球首個開展治療類風濕關節炎臨牀試驗的CD22靶向單抗藥物,對其他免疫性疾病亦具有潛在療效,目前在中國進行III期臨牀試驗,預期將於2021年年底商業化。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account